Butterfly Skin Therapy Pipeline Primed For Transformation

As Amryt's Oleogel-S10 Gets Priority Review

No drugs are approved for epidermolysis bullosa and children with so-called butterfly skin are currently treated by cleaning open wounds and bandaging them. This could soon change.

butterfly
• Source: Archive

The odds of having an approved therapy for epidermolysis bullosa (EB) by the end of 2021 have improved with the news that US regulators have fast-tracked Amryt Pharma's Oleogel-S10 but gene therapies are also coming through the pipeline that could tackle the underlying cause of the rare genetic disorder that causes skin to be extremely fragile.

First up, Ireland's Amryt, which is listed on the NASDAQ and London's AIM market, has revealed that the US Food...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Dermatological

Could Apogee Rival Regeneron/Sanofi, Lilly After Phase II Eczema Data Win?

 
• By 

Apogee Therapeutics reports data from Phase II APEX trial of its long-acting antibody against atopic dermatitis, showing similar efficacy to Regeneron/Sanofi’s Dupixent and Eli Lilly’s Ebglyss.

Novartis’s Cosentyx Suffers Rare Phase III Fail

 
• By 

Multi-blockbuster falls short in a giant cell arteritis study.

What Incyte Investors Expect From New CEO Bill Meury

 

Fresh from having sold Anthos to Novartis, the new CEO is expected to update the oncology and dermatology-focused firm's strategy.

Nektar Bounces Back As Eczema Drug Rezpeg Heads For Phase III

 
• By 

Lilly-rejected candidate impresses in Phase IIb atopic dermatitis trial.

More from Therapy Areas

Investors Back Nuclidium’s Next-Gen Copper-Based Radiopharmaceuticals

 

The Swiss company believes its platform can make radiopharmaceuticals easier to produce and more accessible to patients.

Taiho’s Oral, Mutation-Agnostic DMD Candidate Misses Phase III Endpoint

 
• By 

The oral, twice-daily candidate was expected to control decline in motor function in DMD patients regardless of their gene mutations.

ProKidney Pins Hopes On Accelerated Approval For Rilparencel

 

After posting encouraging Phase II results, the company plans to meet with the US FDA about using data from an ongoing Phase III study for an accelerated approval.